Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Ophthotech Corp. | 3,139,902 | reported | 13 May 2014 | tx 10+3,653,571−3,925,571 |
| PTC THERAPEUTICS, INC. | 2,441,504 | reported | 17 Dec 2013 | tx 6+2,508,171−1,908,162 |
| Nabriva Therapeutics Plc | 2,397,922 | reported | 20 Jul 2017 | tx 10−173,955 |
| IO Biotech, Inc. | 2,365,545 | reported | 09 Nov 2021 | tx 3+2,690,545−188,168 |
| Nabriva Therapeutics AG | 2,334,128 | reported | 14 Sept 2017 | tx 36−386,623 |
| Pacira BioSciences, Inc. | 2,233,993 | reported | 25 Mar 2013 | tx 3−290,900 |
| NOVACEA INC | 1,751,380 | reported | 29 May 2015 | tx 4−20,580 |
| Werewolf Therapeutics, Inc. | 625,995 | reported | 04 May 2021 | tx 2+6,052,814 |
| Mineralys Therapeutics, Inc. | 0 | reported | 14 Feb 2023 | tx 5+3,218,106−31,374,741 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 14 Feb 2023 | CONVERSION | Mineralys Therapeutics, Inc. | 964,238 | — | |
| 14 Feb 2023 | CONVERSION | Mineralys Therapeutics, Inc. | 1,941,368 | — | |
| 14 Feb 2023 | PURCHASE | Mineralys Therapeutics, Inc. | 312,500 | 16.00 USD | first after silence |
| 14 Feb 2023 | CONVERSION | Mineralys Therapeutics, Inc. | 10,411,846 | 0.00 USD | deriv |
| 14 Feb 2023 | CONVERSION | Mineralys Therapeutics, Inc. | 20,962,895 | 0.00 USD | deriv |
| 09 Nov 2021 | CONVERSION | IO Biotech, Inc. | 2,365,545 | — | |
| 09 Nov 2021 | PURCHASE | IO Biotech, Inc. | 325,000 | 14.00 USD | first after silence |
| 09 Nov 2021 | CONVERSION | IO Biotech, Inc. | 188,168 | 0.00 USD | deriv |
| 04 May 2021 | CONVERSION | Werewolf Therapeutics, Inc. | 625,995 | — | |
| 04 May 2021 | CONVERSION | Werewolf Therapeutics, Inc. | 5,426,819 | 0.00 USD | deriv |
| 13 Sept 2017 | SALE | Nabriva Therapeutics AG | 22,721 | 8.54 USD | |
| 12 Sept 2017 | SALE | Nabriva Therapeutics AG | 10,458 | 8.63 USD | |
| 14 Sept 2017 | SALE | Nabriva Therapeutics AG | 3,429 | 8.52 USD | |
| 31 Aug 2017 | SALE | Nabriva Therapeutics AG | 639 | 9.50 USD | |
| 07 Aug 2017 | SALE | Nabriva Therapeutics AG | 17,790 | 10.50 USD | |
| 08 Aug 2017 | SALE | Nabriva Therapeutics AG | 2,013 | 10.50 USD | |
| 28 Jul 2017 | SALE | Nabriva Therapeutics AG | 6,585 | 10.51 USD | |
| 24 Jul 2017 | SALE | Nabriva Therapeutics AG | 160 | 10.50 USD | |
| 19 Jul 2017 | SALE | Nabriva Therapeutics AG | 20,786 | 10.50 USD | |
| 20 Jul 2017 | SALE | Nabriva Therapeutics AG | 23,445 | 10.50 USD | |
| 19 Jul 2017 | SALE | Nabriva Therapeutics Plc | 20,786 | 10.50 USD | |
| 20 Jul 2017 | SALE | Nabriva Therapeutics Plc | 23,445 | 10.50 USD | |
| 18 Jul 2017 | SALE | Nabriva Therapeutics Plc | 1,339 | 10.50 USD | |
| 17 Jul 2017 | SALE | Nabriva Therapeutics Plc | 47,460 | 10.50 USD | |
| 14 Jul 2017 | SALE | Nabriva Therapeutics Plc | 21,055 | 10.53 USD |
2 purchases reported after at least 12 months of silence — most recent on 14 Feb 2023.